Latest "Zenobia Therapeutics" News Stories - Page: 3

13:57 EDT 23rd June 2018 | BioPortfolio

Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Zenobia Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.

Showing "Zenobia Therapeutics" News Articles 51–75 of 6,400+

Probably Relevant

Sandoz targets digital therapeutics

Partners with Pear Therapeutics to launch FDA-approved apps

Abeona Therapeutics Inc: Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease

NEW YORK and CLEVELAND, April 20, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene ther...

Spark Therapeutics, Inc.: Spark Therapeutics veranstaltet am Dienstag, 20. Februar, um 8.30 Uhr ET eine Telefonkonferenz, um über die Ergebnisse des Jahres 2017 und über aktuelle geschäftliche Höhepunkte zu sprechen

PHILADELPHIA, 13. Februar 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), ein voll integriertes Gentherapie-Unternehmen, das infrage stellt, dass genetische Krankheiten unvermeidbar sin...

Repros Therapeutics (RPRX) Set to Announce Earnings on Thursday

Repros Therapeutics will release its earnings data before the market opens on Thursday, March 29th. Analysts expect Repros Therapeutics to post earnings of per share for the quarter.

Novartis plans digital therapeutics for schizophrenia and MS

Will work with Pear Therapeutics on a prescription software range

Addex Therapeutics: Addex Therapeutics Equity Research Report Update Issued by valuationLAB

Addex Therapeutics / Addex Therapeutics Equity Research Report Update Issued by valuationLAB . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the cont...

The Current issue of “The view from here” is concerned with Novel Therapeutics.

The topic of this month’s newsletter from Drug Discovery Today is Novel Therapeutics.

The Current issue of “The view from here” is concerned with Therapeutics

The topic of this month’s newsletter from Drug Discovery Today is “Therapeutics”

Lilly's Olumiant Makes Big Leap In Lupus Trial

A couple of weeks after the setback of getting a worse-than-expected label from the FDA for Olumiant in rheumatoid arthritis...   

Rubius Therapeutics brings in new CEO

Rubius Therapeutics, a biotech that has ambitions to bring “super blood” to the market, has revealed that it has appointed a new CEO to lead the company. Pablo Cagnoni enters the position, joining the biotech from Tizona Therapeutics, which he led as CEO. He joins the company not long after its second successful financing round, after the company raised $100 million in March. read more

PTC Therapeutics FOPO brings in $102.5mm

PTC Therapeutics Inc. (rare disease and cancer therapeutics) netted $102.5mm through the public offering of 4mm shares at $27...

Antibe Therapeutics Looking for More Licensing Deals

Antibe Therapeutics is trying to change the game of non-steroidal anti-inflammatory drugs (NSAID)—the “largest category of drugs globally,” CEO Dan Legault told INN. The post Antibe Therapeutics Looking for More Licensing Deals appeared first on Investing News Network.

Transition Therapeutics licenses drug candidate from Eli Lilly

Transition Therapeutics announced its wholly-owned subsidiary, Transition Therapeutics Ireland Limited, has exclusively licensed worldwide rights to a novel small molecule drug candidate ("TT701") from Eli Lilly and Company. TT701 is a selective androgen receptor modulator that has been shown in a Phase 2 study to significantly increase lean body mass and a measurement of muscle more » The post T...

Spark Therapeutics, Inc.: Spark Therapeutics Enters into a Licensing and Supply Agreement for Investigational Voretigene Neparvovec Outside the U.S.

Novartis Pharmaceuticals will commercialize investigational voretigene neparvovec when and if approved in Europe and all other markets outside the U.S.; Spark Therapeutics retains U.S. commercial r...

Can Digital Therapeutics Substitute for Drugs or Other Therapies?

The various smart phone apps that are being developed to monitor or help manage diseases like diabetes or insomnia are now being referred generally as digital therapeutics (see: Can “Digital Therapeutics” Be as Good as Drugs?). This article provocatively asks the question whether some of these apps can ultimately substitute...

Addex Therapeutics Ltd: Addex Therapeutics Equity Research Report Update Issued by valuationLAB

Report estimates a current value of ADXN of CHF 12.5 per share Geneva, Switzerland, 8 January 2018 - Addex Therapeutics (SIX: ADXN) announced today that the independent life science equity researc...

Topas Therapeutics GmbH: Topas Therapeutics and Boehringer Ingelheim Sign Multi-Year Collaboration and Option Agreement

Companies join forces in immune tolerance to tackle ADA (anti-drug antibodies) Initial focus on next generation vector-based therapeutics Boehringer Ingelheim is granted option to in-license sever...

Roche To Use Lodo Therapeutics' Drug Discovery Platform

NewsUnder the terms of the agreement, Genentech will utilize Lodo Therapeutics’ proprietary genome mining and biosynthetic cluster assembly platform to identify novel molecules with therapeutic potential against multiple disease-related targets of interest to Genentech.

Silence Therapeutics chief executive Mortazavi steps down

RNA therapeutics developer Silence Therapeutics announced on Monday that its chief executive Ali Mortazavi will leave the company with immediate effect after a six year stay. Silence said that unti...

Arcturus Therapeutics Announces Expansion of Collaboration with Takeda Pharmaceuticals to Develop RNA-based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis (NASH) and Other GI Disorders

SAN DIEGO, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, announced today that it is extending its partnership with Takeda Pharmaceutical Company Limited (TSE:4502) (Takeda). Under the collaboration, Takeda and Arcturus will advance their efforts to develop RNA-based therapeutics for the treatment of non-alcoholic steatohepatitis...

In The Spotlight: G1 Therapeutics

Shares of G1 Therapeutics Inc. (GTHX) have returned an impressive 103% year-to-date while the iShares NASDAQ Biotechnology Index (ETF)(IBB) is up a paltry 2.8% during the same period.

Lilly pays $63mm up front for rights to Sigilon's living therapeutics technology

Sigilon Therapeutics Inc. granted Eli Lilly & Co. exclusive global rights to its Afibromer living therapeutics technology for...

Sandoz, Pear to commercialize prescription digital therapeutics

Sandoz, a division of Novartis, and Pear Therapeutics have agreed to jointly commercialize and continue development of novel prescription digital therapeutics designed to treat disease and improve clinical outcomes for patients.

Genentech, Lodo Therapeutics form $969m drug discovery collaboration

Roche’s subsidiary Genentech has entered into a strategic drug discovery collaboration with Lodo Therapeutics, which is focused on the creation of therapeutics derived from nature that will impact patients across the world.

Third Rock Ventures Launches Cedilla Therapeutics to Target Protein Stability Using Small Molecule Therapeutics

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cedilla Therapeutics, a new biotechnology company broadening the reach of small molecule therapeutics by discovering and exploiting unique insights into protein stability, launched today with $56.2 million in Series A funding from Third Rock Ventures. Cedilla is leveraging a growing understanding of the principles that dictate protein stability and appl...

Quick Search


News Quicklinks